Dynavax in clover on Covid-19 vaccine data
Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.
Covid-19 research efforts slow
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Valneva falls as UK contract axe falls
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
No let-up in Covid-19 vaccine trials
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Bavarian Nordic gets a vaccine booster
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
Moderna stakes a claim against Covid-19’s Delta variant
More real-world data emerge backing Covid-19 vaccine efficacy against the Delta variant, and some will see Moderna’s Spikevax as a clear winner.
